ライフサイエンスコーパス: central line

1 mmendation that it be administered through a central line.

2 continued hospitalization or placement of a central line.

3 e of nasogastric tubes, Foley catheters, and central lines.

4 quity hospitals, despite placing 16.2% fewer central lines.

5 bloodstream infections were associated with central lines, 86% of nosocomial pneumonia was associate

6 Bacteremia from frequent central line access was the most common problem.

7 were ventilated, received antibiotics, had a central line, and had 1 additional risk factor (parenter

8 munocompromised patients, 4,135 (20.3%) with central lines, and 2,352 (11.6%) chronically ventilated.

9 alized (aOR, 0.36 [95% CI, .24-.54]), or had central lines (aOR, 0.44 [95% CI, .27-.74]), and associa

10 f invasive bacterial infection, CLABSI, or a central line appears to be associated with bacteremia, w

11 Central line associated bloodstream infections (CLABSIs)

12 ous catheters had decreased association with central-line associated bloodstream infection (odds rati

13 l venous catheter: 6.29/1,000 line days) and central-line associated bloodstream infection (periphera

14 rs associated with BCC and related outcomes (central-line associated bloodstream infection [CLABSI] a

15 e variables postulated to be associated with central-line associated bloodstream infection and venous

16 atheters are associated with higher rates of central-line associated bloodstream infection and venous

17 BCC was associated with increased central-line associated bloodstream infection rates.

18 cant predictors of venous thromboembolism or central-line associated bloodstream infection.

19 are associated with complications, including central-line associated bloodstream infections and venou

20 sitive cocci-related, skin flora-related, or central line-associated bacteremia in patients with hema

21 Central line-associated blood stream infection (CLABSI)

22 Central line-associated blood stream infections (CLABSI)

23 Hospital-acquired infections other than central line-associated blood stream infections were inf

24 Central line-associated bloodstream infection (BSI) rate

25 We describe central line-associated bloodstream infection (CLABSI) p

26 record (EHR) data to evaluate differences in central line-associated bloodstream infection (CLABSI) r

27 th ventilator-associated pneumonia (VAP) and central line-associated bloodstream infection (CLABSI) r

28 Central line-associated bloodstream infection (CLABSI) r

29 entionists (IPs) conducting surveillance for central line-associated bloodstream infection (CLABSI) w

30 istory of bacteremia, osteomyelitis, stroke, central line-associated bloodstream infection (CLABSI),

31 Occurrence of central line-associated bloodstream infection (CLABSI),

32 days after PICU admission) and PICU rates of central line-associated bloodstream infection (CLABSI),

33 st strategy that can reduce the incidence of central line-associated bloodstream infection (CLABSI).

34 gest period a central line remains free from central line-associated bloodstream infection during an

35 nfection control precautions on our rates of central line-associated bloodstream infection in critica

36 pin significantly decreased the incidence of central line-associated bloodstream infection in the med

37 Incidence of central line-associated bloodstream infection in the med

38 The incidence of central line-associated bloodstream infection per 1000 p

39 days to the end of day 9, giving an adjusted central line-associated bloodstream infection rate of 0.

40 ished by the end of day 7 giving an adjusted central line-associated bloodstream infection rate of 1.

41 An adjusted central line-associated bloodstream infection rate was c

42 decrease of 0.05 unit in the post-Directive central line-associated bloodstream infection rates asso

43 Central line-associated bloodstream infection rates were

44 central line removed by day 7, zero risk for central line-associated bloodstream infection should be

45 The lowest probability identified for central line-associated bloodstream infection was 1 in 1

46 ection-free before the lowest probability of central line-associated bloodstream infection, 1 in 100

47 density of ventilator-associated pneumonia, central line-associated bloodstream infection, and cathe

48 nocycline and rifampin use and a decrease in central line-associated bloodstream infection, because o

49 ontrol group for 14 outcomes (ICU mortality, central line-associated bloodstream infection, ventilato

50 tion, Clostridium difficile infection (CDI), central line-associated bloodstream infection, ventilato

51 e unit were subjects for the surveillance of central line-associated bloodstream infection.

52 sitive cocci-related, skin flora-related, or central line-associated bloodstream infection.

53 rifampin are proven to decrease the rates of central line-associated bloodstream infection; however,

54 95% CI, -31% to -1%; P = .03) and 64% fewer central line-associated bloodstream infections (3.4 vs 9

55 ociated urinary tract infections (CAUTI) and central line-associated bloodstream infections (CLABSI)

56 We evaluated the incidence of VTE, central line-associated bloodstream infections (CLABSIs)

57 aid Services imparts financial penalties for central line-associated bloodstream infections (CLABSIs)

58 lood cultures, is sometimes used to diagnose central line-associated bloodstream infections (CLABSIs)

59 ying modifiable risk factors associated with central line-associated bloodstream infections (CLABSIs)

60 There are no systematic measures of central line-associated bloodstream infections (CLABSIs)

61 are and Medicaid Services to publicly report central line-associated bloodstream infections (CLABSIs)

62 Central line-associated bloodstream infections (CLABSIs)

63 Healthcare-associated central line-associated bloodstream infections (CLABSIs)

64 mary prespecified outcome was a composite of central line-associated bloodstream infections (CLABSIs)

65 acy of antimicrobial lock therapy to prevent central line-associated bloodstream infections (CLABSIs)

66 Factors that increase the risk of central line-associated bloodstream infections (CLABSIs)

67 ify 2 cohorts: (1) nondialysis patients with central line-associated bloodstream infections (CLABSIs)

68 quality improvement interventions to prevent central line-associated bloodstream infections (CLABSIs)

69 e in falls (P = .02) and a 37.7% increase in central line-associated bloodstream infections (P = .04)

70 tion was driven by the cases associated with central line-associated bloodstream infections and endoc

71 nvolving evidence-based practices to prevent central line-associated bloodstream infections and the C

72 ion and providing further evidence that most central line-associated bloodstream infections are preve

73 pact of quality improvement interventions on central line-associated bloodstream infections in adult

74 positive bloodstream infections and possible central line-associated bloodstream infections in preter

75 Baseline average central line-associated bloodstream infections per 1,000

76 acquired adverse events, including falls and central line-associated bloodstream infections, along wi

77 Survey), health care-associated infections (central line-associated bloodstream infections, catheter

78 was independently associated with male sex, central line-associated bloodstream infections, long-ter

79 was independently associated with male sex, central line-associated bloodstream infections, long-ter

80 sociated with mortality, PICU complications, central line-associated bloodstream infections, or venti

81 iciency, in-hospital mortality, incidence of central line-associated bloodstream infections, ventilat

82 prevention (IP) practices, particularly for central line-associated bloodstream infections.

83 nterventions contribute to the prevention of central line-associated bloodstream infections.

84 he multifaceted intervention and the reduced central line-associated bloodstream infections.

85 The incidence of MRSA central line-associated BSI has been decreasing in recen

86 In all ICU types, MSSA central line-associated BSI incidence declined from 1997

87 From 2001 through 2007, MRSA central line-associated BSI incidence declined significa

88 = .02) in the 1997-2007 period, overall MRSA central line-associated BSI incidence decreased 49.6% (P

89 coronary units experienced increases in MRSA central line-associated BSI incidence in the 1997-2001 p

90 Declines in MRSA central line-associated BSI incidence ranged from -51.5%

91 07 were used to calculate pooled mean annual central line-associated BSI incidence rates for 7 types

92 sion modeling to estimate percent changes in central line-associated BSI metrics over the analysis pe

93 fection preventionist and computer algorithm central line-associated BSI rates were 3.3 (interquartil

94 Unit-specific central line-associated BSI rates were calculated for 12

95 stitutional comparisons of publicly reported central line-associated BSI rates.

96 ant variation in the application of standard central line-associated BSI surveillance definitions acr

97 Variation in central line-associated BSI surveillance practice may co

98 patient-days of surveillance; 2498 reported central line-associated BSIs (7.4%) were MRSA and 1590 (

99 Although the overall proportion of S. aureus central line-associated BSIs due to MRSA increased 25.8%

100 SA was defined as the proportion of S aureus central line-associated BSIs that were MRSA.

101 Overall, 33,587 central line-associated BSIs were reported from 1684 ICU

102 infections (17.4%, of which only 10.5% were central line-associated), non-C. difficile intra-abdomin

103 gram-positive-cocci-, skin-flora-related, or central-line-associated bacteremia in patients with hema

104 gram-positive cocci, skin-flora-related, or central-line-associated bloodstream infection.

105 ngitudinal multicenter cohort study included central-line-associated bloodstream infections (CLABSIs)

106 coccal biofilms are the most common cause of central-line-associated bloodstream infections, and anti

107 ine, respondents were more likely to place a central line at higher norepinephrine doses of 0.5 ug/kg

108 ject will not be limited to an infinitesimal central line but will have a finite extent, which is rel

109 s in diagnostic criteria and improvements in central line care.

110 We tested a novel, central line catheter-based, transvenous phrenic nerve p

111 tions (CLABSIs) may lead to modifications to central line (CL) management.

112 years and had complex chronic conditions or central lines compared to non-BSI patients.

113 The Lokich regimen was associated with more central line complications and hand-foot syndrome.

114 the presence of a right-sided aortic arch, a central line could be erroneously inserted into the arte

115 oup also reduced infection rates to <1/1,000 central line days (a 69% reduction) at 12 months.

116 bloodstream infection (CLABSI) rates by how central line days are counted: once a day at a fixed tim

117 intervention group sustained rates <1/1,000 central line days at 19 months (an 81% reduction).

118 -associated bloodstream infections per 1,000 central line days was 4.48 and 2.71, for the interventio

119 medical-surgical ICUs (0.31 vs 0.15 per 1000 central line days) to -69.2% (95% CI, -57.9% to -77.7%;

120 001) in surgical ICUs (0.24 vs 0.10 per 1000 central line days) to -77.7% (95% CI, -68.2% to -84.4%;

121 001) in surgical ICUs (0.58 vs 0.18 per 1000 central line days).

122 .001) in medical ICUs (0.40 vs 0.09 per 1000 central line days).

123 a total of 10,866 CLABSI cases and 9,543,765 central line days.

124 bloodstream infections (3.4 vs 9.4 per 1000 central line days; ratio, 0.36; 95% CI, 0.16 to 0.81; P

125 ce utilization decreased from 24.05 to 22.07 central line-days per 100 patient-days.

126 e rates, and CLABSI incidence rates per 1000 central line-days were calculated.

127 tional surveillance (2.4 infections per 1000 central line-days) had the highest rate by computer algo

128 computer algorithm (12.6 infections per 1000 central line-days).

129 and 9.0 (IQR, 6.3-11.3) infections per 1000 central line-days, respectively.

130 epresenting 241,518 patient-days and 165,963 central line-days.

131 1500 g) (1318 infants [76.5%]), and/or had a central line during their hospital stay (1509 infants [8

132 Compliance with the insertion bundle for central lines during the first 12-month roll-out period

133 ith prior antibiotic exposure, presence of a central line, endotracheal intubation, and prior fungal

134 dulafungin administration into the heart via central line, exposure is likely extreme enough to induc

135 lementation of prevention initiatives beyond central lines has not received the same level of acknowl

136 onal isolates of bacteremia in patients with central lines in an oncology ward (OW), with comparison

137 factors were effort-related (87%) in G1 and central lines in G2neonates (100%) and in G2non-neonates

138 eceive arsenic trioxide because of transient central line-induced cardiac arrhythmia, and another rec

139 ed 2 infectious complications (pneumonia and central line infection, both requiring hospitalization)

140 d an episode of severe sepsis secondary to a central line infection, treatment of sepsis is discussed

141 There were fewer central line infections per 1000 catheter days, fewer ca

142 rovement interventions to reliably implement central line insertion and maintenance bundles on CLABSI

143 All patients in whom subclavian central line insertion is planned should have both sides

144 , lower extremity fracture, pelvic fracture, central line, intracranial hemorrhage, and blood transfu

145 es the presence of a predominant clone among central line isolates from an OW that is not present in

146 In case of any difficulties with central lines, it is necessary to investigate the underl

147 here were small changes in the extent of the central line of block.

148 only demonstrate that the PP-InsPs provide a central line of communication between signaling and meta

149 tion from a discrete midlateral right atrial central line of conduction block to the inferior vena ca

150 Because the central line of Gd(2)@C(79)N is due to the Kramer's doub

151 Within affective science, the central line of inquiry, animated by basic emotion theor

152 Despite a central line of research aimed at quantifying relationsh

153 to ammonium (NH(4)(+)) removal following two central lines of evidence: (i) Similar transformation pr

154 Thus, in patients with permanent central lines or pacemakers, both corrected and uncorrec

155 Biofilm formation on central lines or peripheral catheters is a serious threa

156 e use: coagulase-negative staphylococci with central lines, P. aeruginosa and Acinetobacter species w

157 le donors had higher rates of AEs, requiring central line placement more often (17% vs 4%, P< .001),

158 y required critical care, blood transfusion, central line placement, mechanical ventilation, and surg

159 ose control and ultrasonography for reducing central-line placement complications.

160 Identify the longest period a central line remains free from central line-associated b

161 [IQR 14-35] vs 14 [6-20] days; p<0.0001) and central-line removal (587 [76%] of 776 vs 538 [59%] of 9

162 actors, all-cause mortality, antifungal use, central-line removal, and ophthalmological and echocardi

163 s of intensive care unit patients have their central line removed by day 7, zero risk for central lin

164 a catheter is low and, when obtained from a central line, statistically less than from a peripheral

165 The central line team at hospital cooperating with other spe

166 ldren (1.2%) who had deep vein thrombosis or central-line thrombosis as their most recent VTE.

167 es regardless of the phase of the project or central line type.

168 For dialysis and unspecified central line types, the close to infection-free period w

169 inserted central catheters, and unspecified central line types.

170 resence of fever, comorbidities (intravenous central lines, urinary catheters, diabetes mellitus, AID

171 The donor-matched study group had lower central line utilization (21.4% versus 75%, P = 0.045),

172 -lymphocyte preparations be administered via central line, vascular shunt, or arteriovenous fistula t

173 Intensive care unit adult patients whose central line was inserted in the intensive care unit.

174 lon, number of line infections, or number of central lines were found.

175 Central lines, which are essential for treating cancer,

176 The spectrum exhibits a central line with a sub-recoil linewidth as low as appro